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Immune responses and the components of protective immunity following norovirus infection in humans are
poorly understood. Although antibody responses following norovirus infection have been partially character-
ized, T cell responses in humans remain largely undefined. In contrast, T cells have been shown to be essential
for viral clearance of mouse norovirus (MNV) infection. In this paper, we demonstrate that CD4 T cells
secrete gamma interferon (IFN-) in response to stimulation with MNV virus-like particles (VLPs) after MNV
infection, supporting earlier reports for norovirus-infected mice and humans. Utilizing this model, we immu-
nized mice with alphavirus vectors (Venezuelan equine encephalitis [VEE] virus replicon particles [VRPs])
expressing Norwalk virus (NV) or Farmington Hills virus (FH) virus-like particles to evaluate T cell epitopes
shared between human norovirus strains. Stimulation of splenocytes from norovirus VRP-immunized mice
with overlapping peptides from complete libraries of the NV or FH capsid proteins revealed specific amino acid
sequences containing T cell epitopes that were conserved within genoclusters and genogroups. Immunization
with heterologous norovirus VRPs resulted in specific cross-reactive IFN- secretion profiles following stim-
ulation with NV and FH peptides in the mouse. Identification of unique strain-specific and cross-reactive
epitopes may provide insight into homologous and heterologous T cell-mediated norovirus immunity and
provide a platform for the study of norovirus-induced cellular immunity in humans.
Norovirus infection is characterized by the induction of both
humoral and cellular immune responses. Humoral immunity in
humans following norovirus infection has been described in
detail for a limited number of norovirus strains (8, 10, 12, 17,
18, 29). Humans mount specific antibody responses to the
infecting strain, which bear complex patterns of unique and
cross-reactive, yet undefined, epitopes to other strains within
or across genogroups (23, 29). Short-term immunity following
homologous norovirus challenge has been documented, but
long-term immunity remains controversial (16, 25). Further-
more, no studies to date have demonstrated cross-protection
following heterologous norovirus challenge (30). While some
susceptible individuals can become reinfected with multiple
norovirus strains throughout their lifetimes, the mechanism of
short-term protection and the impact of previous exposures on
susceptibility to reinfection remain largely unknown.
The role of T cells in controlling norovirus infection also
remains largely undefined. A single comprehensive study de-
tailing immune responses in genogroup II Snow Mountain
virus-infected individuals revealed that CD4 TH1 cells can be
stimulated by virus-like particles (VLPs) to secrete gamma
interferon (IFN-) and interleukin-2 (IL-2) (17). Furthermore,
heterologous stimulation from VLPs derived from different
norovirus strains within but not across genogroups also in-
duced significant IFN- secretion compared to that for unin-
fected individuals (17). A follow-up study with genogroup I
Norwalk virus (NV)-infected individuals confirmed high T cell
cross-reactivity within a genogroup as measured by IFN- se-
cretion (18). Further, vaccination of humans with VLPs also
results in short-term IFN- production (27).
Because norovirus infection studies in humans are con-
founded by previous exposure histories, the use of inbred mice
maintained in pathogen-free environments allows for the study
of norovirus immune responses in a naive background. While
mice cannot be infected with human norovirus strains, VLP
vaccines expressing norovirus structural proteins induce im-
mune responses that can be measured and studied (14, 20).
Mice immunized orally or intranasally with VLP vaccines in
the presence of adjuvant similarly induced CD4 IFN- re-
sponses in Peyer’s patches and spleen (22, 26). Induction of
CD8 T cells and secretion of the TH2 cytokine IL-4 were
separately noted; however, it is unclear if these responses were
influenced by VLPs or the coadministered vaccine adjuvants
(22, 26). Further, coadministration of alphavirus adjuvant par-
ticles with multivalent norovirus VLP vaccine, including or
excluding mouse norovirus (MNV) VLPs, resulted in signifi-
cantly reduced MNV loads following MNV challenge (21).
Multivalent VLP vaccines induced robust receptor-blocking
antibody responses to heterologous human strains not in-
cluded in the vaccine composition (20, 21). Moreover, natural
infection with MNV supports a role for T cell immunity in viral
clearance and protection (5).
To advance our understanding of the scope of the cellular
immune response within and between strains, we immunized
mice with Venezuelan equine encephalitis (VEE) virus repli-
con particles (VRPs) expressing norovirus VLPs derived from
the Norwalk virus (GI.1-1968) (1) or Farmington Hills virus
(FH) (GII.4-2002) (19) strains and analyzed splenocytes for
cytokine secretion, epitope identification, and heterologous
stimulation. The data presented here indicate that the major
capsid proteins of genogroup I and II noroviruses contain
robust T cell epitopes that cross-react with related strains in
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the mouse yet also occur within regions of known variation,
especially among the GII.4 noroviruses.
MATERIALS AND METHODS
VRP immunization and MNV infection. VRPs were produced as described by
Harrington et al. (15). MNV-1 was produced as described by Chachu et al. (6).
Six-week-old BALB/c mice (n  4/experiment) were infected with 3  107 PFU
MNV-1 orally as described previously (6) or were immunized with 2.5  106
VRP-expressing norovirus VLPs or a short noncoding sequence (null VRP) at
days 0 and 21.
Splenocyte stimulation. Spleens were harvested at 3 weeks postboost. Individ-
ual splenocytes were obtained by manual separation, filtration, and lysis of red
blood cells. Cells were cultured at 1  106 cells/well in 96-well cell culture-treated
plates in 100 l complete RPMI medium containing one of the following: VLPs
(1 g/ml), individual NV or FH peptides or peptide pools (1 g/ml/peptide), or
no stimulant. Splenocytes were cultured for 48 h, at which time supernatants
were harvested and stored at 80°C. VLPs were produced as described by
LoBue et al. (20). Complete overlapping 15-mer (5) peptide libraries spanning
the entire NV (GI.1-1968) and FH (GII.4-2002) capsids and truncated stimula-
tory peptides were synthesized at the UNC peptide synthesis core facility. Lyo-
philized peptides were resuspended in phosphate-buffered saline (PBS); insolu-
ble peptides were further dissolved in 1:1 acetonitrile-PBS. CD4 and CD8 T
cell depletions were performed following disruption using QuadroMACS mag-
netic bead separation (Miltenyi) per the manufacturer’s instructions followed by
stimulation as described above. Background levels often increased in concor-
dance with the number of stimulatory peptides used in an assay.
IFN- EIA. IFN- concentrations in splenocyte culture supernatants were
determined by enzyme immunoassay (EIA) (BD Pharmingen) per the manufac-
turer’s instructions. t tests were performed to measure statistical differences
between sample groups of two. All other statistical analyses were performed
using one-way analysis of variance (ANOVA) and the Tukey posttest. In the
figures, error bars indicate standard deviations and P values are indicated as
follows: *, P  0.05; **, P  0.01; ***, P  0.001.
Sequence alignments. Stimulatory sequences identified using 15-mer peptides
within the NV and FH capsids were aligned with sequences representing the
entire VLP panel using Vector NTI software.
RESULTS
CD4 T cells secret IFN- after homotypic VLP stimulation
in MNV-infected mice. There have been few reports on no-
rovirus T cell cross-reactivity comparing norovirus strains,
which can differ genetically by 50% in the capsid amino
acid sequence (11). The ORF2 capsid gene of MNV-1 is
roughly 40% identical to the NV and FH capsid genes.
Given the near absence of human-derived T cell samples
collected from characterized norovirus outbreaks and a tis-
sue culture-adapted virus, we have cloned the antigenic
ORF2 capsid genes from multiple norovirus strains into
alphavirus vectors that, when expressed, form VLPs that can
be simultaneously used as immunogens in vivo in mice and
as antigenic reagents in vitro (15, 20).
To begin to evaluate cross-reactivity among norovirus VLPs,
we immunized mice with live MNV, harvested splenocytes, and
stimulated splenocyte cultures with a panel of VLPs as de-
scribed in Materials and Methods. VLP-stimulated culture su-
pernatants contained elevated levels of IFN- following ho-
mologous MNV VLP stimulation but not heterologous human
norovirus VLP stimulation (P  0.001) (Fig. 1). To identify the
cellular source of IFN- secretion following infection with
MNV, splenocytes were depleted of CD4 and/or CD8 T
cells. Depleted cell suspensions were stimulated with MNV
VLPs or unstimulated and cultured in parallel. Supernatants
were then collected and IFN- secretion measured by EIA.
Splenocytes depleted of CD4 T cells secreted significantly
less IFN- than CD8-depleted splenocytes (P  0.05) (Fig.
2), suggesting that IFN- secretion following MNV infection is
also mediated by CD4 cells. These observations of IFN-
FIG. 1. Splenocyte stimulation with norovirus VLP panel following live MNV immunization. Splenocytes from mice immunized with live MNV
GV-2003 were harvested and stimulated with each individual VLP at 1 g/ml. After incubation for 48 h, culture supernatants were analyzed for
IFN- by EIA (BD Pharmingen). Significant IFN- secretion occurred following MNV VLP stimulation (P  0.001); human-derived VLPs did not
elicit an IFN- response.
FIG. 2. CD4 and CD8 T cell-depleted splenocyte stimulation.
CD4 and/or CD8 T cells were depleted from splenocyte prepara-
tions from mice infected with MNV GV-2003 using marker-specific
depleting antibodies conjugated to magnetic beads as directed by the
manufacturer (Miltenyi). Depleted splenocytes (90% pure) were
stimulated with MNV VLPs for 48 h and supernatants analyzed for
IFN- by EIA. CD4/CD8-depleted cultures and undepleted cul-
tures secreted significantly more IFN- than CD4/CD8- and CD4/
CD8-depleted cultures and unstimulated controls (P  0.05).
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secretion by CD4 T cells in response to a VLP within but not
outside the infecting norovirus genogroup correspond with
findings in humans infected with norovirus (17), indicating that
the immune response to MNV infection in mice may correlate
with the immune response to norovirus infection in humans.
Stimulation with overlapping peptide libraries facilitates
identification of T cell epitopes. Immunization of mice with
VRPs containing norovirus ORF2 sequences results in an an-
tinorovirus immune response characterized by production of
broadly reactive, ligand-blocking antibody in both serum and
the gut (15, 20, 21), which provides protection from MNV
infection (21). These experiments suggest that human norovi-
ruses share common antibody epitopes, as has been reported
using sera from norovirus-infected humans (9, 13, 17, 18, 24).
Thus, we chose to utilize this proven immunization approach
to evaluate cross-reactive T cell epitopes in a manner similar to
that used in studies evaluating antibody epitopes. We immu-
nized BALB/c mice with VRP-NV, VRP-FH, or null VRP
(VRP control) and harvested splenocytes. Splenocytes from
unimmunized mice were treated in parallel. Peptide libraries
representing NV GI.1-1968 and FH GII.4-2002 were sequen-
tially divided into five overlapping pools, as shown in Table 1.
Splenocytes were stimulated with individual peptide pools
composed of 1 g/ml each peptide and supernatants analyzed
for IFN- by EIA.
Splenocytes from VRP-NV-immunized mice secreted signif-
icantly higher levels of IFN- following stimulation with NV
peptide pool 1 (amino acids 1 to 105 [Table 1]) than following
stimulation with other NV peptide pools or controls (P 
0.001) (Fig. 3A). Immunization with null VRP, which does not
express a transgene from its internal promoter, did not result in
splenocyte stimulation by NV peptides (Fig. 3A). Sequential
overlapping peptide pools consisting of two peptides each from
NV peptide pool 1 were then used to stimulate splenocytes
from VRP-NV-immunized mice (Fig. 3B). Pools containing
NV peptides 8-9 and 9-10 were positive for IFN- stimulation
compared to all other overlapping peptides, suggesting an
epitope in peptide 9 (P  0.01). Individual and sequentially
overlapping peptides flanking peptide 9 were used to confirm
this finding (Fig. 3C). These data suggest that a stimulatory T
cell epitope resides in the shell domain of the NV capsid within
sequence FDLSLGPHLNPFLLH spanning amino acids 81 to
95 (Fig. 3D).
In contrast, splenocytes from VRP-FH-immunized mice se-
creted significantly higher levels of IFN- following stimulation
with FH peptide pool 5 (amino acids 431 to 540 [Table 1]) than
following stimulation with other FH peptide pools (P  0.001)
(Fig. 4A). Cultures from mice immunized with null VRP or
unimmunized controls were not stimulated by FH pool 5 (P 
0.001) (Fig. 4A). Sequentially overlapping pools and individual
peptides within FH peptide pool 5 were then used to stimulate
splenocytes from VRP-FH-immunized mice as described
above (Fig. 4B and C). Overlapping peptides 45-46 induced
significantly higher levels of IFN- than peptides 46-47 (P 
0.01) and all other overlapping groups (P  0.001) (Fig. 4B).
Peptides 46-47 and 47-48 also induced higher levels than all
remaining overlapping groups (P  0.001). Upon closer eval-
uation, stimulation with individual or overlapping peptides
containing peptide 46 induced significant IFN- responses
compared to individual peptide 45 or 48 (P  0.05) but not
peptide 47 (Fig. 4C). Stimulation with individual or overlap-
ping peptides containing peptide 47 also induced IFN- secre-
tion that was elevated above that with peptide 45 or 48 stim-
ulation, but this was not significant. Together, these data
suggest that peptides 46 and 47 spanning amino acids 461 to
485 of sequence CLLPQEWVQHFYQEAAPAQSDVALL in
the P1 capsid domain contain one or two distinct T cell stim-
ulatory epitopes (Fig. 4D).
Stimulatory sequences are conserved within genoclusters
and genogroups. To determine if the identified stimulatory
sequences within NV and FH are conserved across additional
norovirus strains, we performed alignments of corresponding
sequences from our panel of VLPs (Fig. 5). Alignments re-
vealed that sequences from two NV-like strains within the GI.1
genocluster were completely conserved (Fig. 5A). Further-
more, the stimulatory sequence was also highly conserved
(86.7%) across all other GI sequences tested but was only
46.7% conserved when aligned with GII sequences. Stimula-
tory FH sequences were highly conserved (91.7%) within the
GII.4 genocluster among seven time-ordered strains analyzed.
The sequentially evolved LV 1997, FH 2002a, and FH 2002
sequences (19), as well as the recently isolated Minerva 2006
sequence (4), were identical. A single amino acid difference
was noted with other contemporary isolates. However, se-
quences of additional strains within GII (60%) or in GI (40%)
were not as highly conserved (Fig. 5b).
To directly evaluate stimulatory-sequence cross-reactivity
among norovirus strains, groups of mice were individually im-
munized with VRPs expressing VLPs from NV GI.1-1968, FH
GII.4-2002, heterologous GI, heterologous GII, or MNV
strains, and splenocytes were stimulated with NV peptide 9,
FH peptide 46, or FH peptide 47. Mice immunized with VRP-
WC, a GI.1-2001 (18) NV-like VLP having an identical corre-
sponding sequence to NV peptide 9, had strong IFN- re-
sponses to peptide 9 stimulation that were significantly higher
than those in all other immunization groups (P  0.01) (Fig.
6A). In contrast, immunization with heterologous GI strains in
TABLE 1. Norwalk virus and Farmington Hills virus capsid peptide
library sequences

















a As described in reference 3.
b The pool contains a stimulatory peptide(s).
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genoclusters different from that of NV, as well as GII and
MNV strains, elicited no IFN- responses following peptide 9
stimulation (Fig. 6A). These results suggest that although se-
quences corresponding to peptide 9 within heterologous GI
appear to be highly conserved, the stimulatory epitope requires
complete identity for cross-reactivity, which is maintained only
within the GI.1 genocluster. Because only the serine (S) resi-
due at position 84 is different in NV and several heterologous
GI sequences, S may be an integral residue required for
epitope recognition (Fig. 5A).
Cross-reactive secretion of IFN- in response to FH peptide
46 and 47 stimulation was very robust following immunization
with heterologous GII.4 strains LV 1987, LV 1997, Hunter
2004, and Sakai 2005 (Fig. 6B) and was significantly higher
than IFN- levels induced following non-GII.4 immunization
in most groups (Fig. 6C) (P  0.05 to 0.001). Additionally,
IFN- levels following stimulation in heterologous GII-im-
mune cultures M7 (P  0.01) and HV (P  0.05) were signif-
icantly higher than those in GI- or MNV-immune cultures,
where IFN- secretion was absent (Fig. 6c). Unstimulated con-
trol splenocyte cultures from each immunization group did not
secrete significant amounts of IFN- (Fig. 6A to C). Together,
these data indicate that GII strains within and outside the
GII.4 genocluster maintain epitope integrity with various
amounts of sequence variation.
Deletion of N-terminal and C-terminal residues of stimula-
tory sequences reveal likely NV and FH T cell epitopes. Trun-
cated peptides of the original stimulatory NV9 sequence lack-
ing one or two residues from the N terminus (9N	1 and 9N	2)
or one or two residues from the C terminus (9C	1 and 9C	2)
were synthesized and used to stimulate splenocytes from VRP-
NV-immunized mice. Likewise, truncated FH46 and FH47
peptides lacking two residues from each terminus were synthe-
sized (46N	2, 46C	2, 47N	2, and 47C	2) and used to stim-
ulate splenocytes from VRP-FH-immunized mice. IFN- lev-
els following stimulation with 9N	1, 9N	2, and 9C	1 were not
different from levels following stimulation with the uncompro-
mised NV9 peptide, (Fig. 7A). On the contrary, stimulation
with 9C	2 resulted in IFN- secretion below background lev-
els. These data show that from the original NV peptide se-
quence (FDLSLGPHLNPFLLH), the T cell epitope is con-
tained within the sequence LSLGPHLNPFLL for BALB/c
mice.
Stimulation of FH-immune splenocyte cultures with 46N	2
resulted in significantly lower levels of IFN- secretion,
whereas stimulation with 46C	2 did not affect IFN- secretion
FIG. 3. Norwalk capsid peptide stimulation. (A) Splenocytes from mice immunized with VRP-NV-GI.1-1968, null VRP, or no immunogen were
stimulated with overlapping peptide pools of 10 to 11 peptides spanning the entire capsid and supernatants tested for IFN-. (B) Overlapping sets
of peptides from stimulatory pools were used to stimulate splenocytes from VRP-NV-immunized mice to identify stimulatory peptides. (C) In-
dividual and overlapping peptides were then used to identify peptides containing stimulatory sequences. (D) Stimulatory peptide sequences.
Peptides in NV pool 1 (A) stimulated IFN- secretion significantly more than other pools (P  0.001). Overlapping peptides 8-9 and 9-10
stimulated IFN- secretion significantly more than all other overlapping pairs (P  0.01) (B) and more than peptide 8 or 10 alone (P  0.05) (C).
VOL. 84, 2010 NOROVIRUS T CELL EPITOPES 8533
compared to stimulation with the original FH peptide 46 (Fig.
7B). Stimulation with both 47N	2 and 47C	2 resulted in sig-
nificantly decreased IFN- secretion compared to stimulation
with full-length peptide. These data suggest that the epitope
sequence contained within peptide 46 includes residues CLL
PQEWVQHFYQ. The secondary epitope within peptide 47
cannot be deduced from these data; however, we can conclude
that at least one residue contiguous with each terminus is
required for epitope integrity in BALB/c mice. We can also
conclude that peptides 46-47 likely contain two independent
epitopes rather than one overlapping epitope due to main-
tained stimulation following deletion of the C-terminal resi-
dues of peptide 46 and loss of activity following deletion of the
N-terminal residues of peptide 47, which are equivalent resi-
dues and unlikely to have different phenotypes in mutual
epitopes.
DISCUSSION
The components of protective immunity in human norovirus
infection are unknown. Understanding the mechanisms gov-
erning norovirus immunity is not only essential for develop-
ment of efficacious norovirus vaccines and therapeutics but
likely required for understanding differential outcomes of viral
pathogenesis following repeat infections. Two vaccine strate-
gies for norovirus immune induction are currently being eval-
uated: (i) oral or intranasal administration of VLPs and (ii)
VRP expression of VLPs in vivo following subcutaneous ad-
ministration. Oral administration of VLP vaccines in humans,
while safe and immunogenic, has been shown to induce very
weak humoral and cellular immune responses to norovirus
compared to norovirus infection and likely will require adju-
vant enhancements (27). In contrast, alphavirus VRPs induce
strong mucosal, cellular, and humoral immune responses to
the expressed transgene, including norovirus VLPs in mice (7,
15, 28), and, importantly, have been shown to be safe and
effective in humans (2).
The emergence of literature documenting T cell responses
following norovirus infection in humans or immunization in
mice suggests that the cellular immune response is a poten-
tially important component in norovirus vaccine design. Cha-
chu et al. (5) recently showed that both CD4 and CD8 T
cells participate in viral clearance mechanisms following MNV
infection. Findings from our group and others specifically sup-
port CD4 TH1 T cells as likely candidates responsible for
IFN- secretion in response to norovirus challenge, including
MNV challenge (17, 22, 26, 27) (Fig. 2). The TH1 cytokine
IFN- was elevated in splenocyte culture supernatants follow-
ing stimulation with norovirus peptides (Fig. 3, 6, and 7). Pre-
vious work reported by our group also showed that VRPs
FIG. 4. Farmington Hills capsid peptide stimulation. (A) Splenocytes from mice immunized with VRP-FH-GII.4-2002, null VRP, or no
immunogen were stimulated with overlapping peptide pools of 10 to 11 peptides spanning the entire capsid and supernatants tested for IFN-.
(B) Overlapping sets of peptides from stimulatory pools were used to stimulate splenocytes from VRP-NV-immunized mice to identify stimulatory
peptides. (C) Individual and overlapping peptides were then used to identify peptides containing stimulatory sequences. (D) Stimulatory peptide
sequences, with overlapping regions underlined. IFN- was significantly higher following stimulation with FH pool 5 than with the other pools (P 
0.001) (A). Overlapping peptides 45-46 induced increased IFN- secretion compared to peptides 46-47 (P  0.01) and all other overlapping
peptides (P  0.001) (B). Peptides 46-47 and 47-48 induced increased IFN- secretion compared to all other overlapping peptides (P  0.001) (B).
Stimulation with individual and overlapping peptides containing peptide 46 were significantly higher than that with peptide 45 or 48 alone (P 
0.05) (C).
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induce IgA and IgG responses at mucosal surfaces that can
block virus-receptor ligand interactions (20). Together these
data suggest that norovirus vaccination with VRPs may be a
promising strategy for individuals in environments with a high
risk of exposure, such as hospitals and primary care facilities.
To facilitate vaccine design and begin to decipher complex
cross-reactive responses, we have begun to characterize T cell
responses to homologous and heterologous norovirus capsid
peptides following VRP immunization in the mouse. Although
it is unlikely that specific murine and human T cell epitopes are
conserved across species, we can determine murine-specific
epitopes contained within human norovirus strains and their
relative conservation across genetically related norovirus
strains as a surrogate model. This information will likely be
useful in determining if previous exposure to or vaccination
against heterologous strains can confer T cell-mediated pro-
tection upon subsequent challenge and in informing future
human studies.
Unknown preexposure histories in humans can skew cross-
reactivity profiles and are highly variable between individuals,
and thus we used norovirus-naive mice to provide a clearer
view of T cell cross-reactivity between strains. Mice immunized
with live MNV mount a specific homotypic response to MNV
VLPs but did not mount cross-genogroup reactive IFN- re-
sponses when stimulated with heterologous human-derived
VLPs, mimicking results found in norovirus-infected humans.
Our results indicate that T cell responses following VRP vac-
cination to one norovirus strain are cross-reactive to heterol-
ogous norovirus peptides when sequence homology is highly
conserved (Fig. 6). These data support previous findings by
Lindesmith et al. (17) showing that peripheral blood mononu-
clear cells (PBMCs) from humans infected with a GII.2 SMV
strain cross-reacted to stimulation with VLPs from GII.1 HV
strain but much less so to GI VLPs. Peptides can be used not
only to determine cross-reactivity between strains but also to
identify specific T cell epitopes, making them particularly ad-
vantageous immunogens. Stimulation with peptides resulted in
robust IFN- secretion from identifiable pools (Fig. 3A and
4A); however, stimulatory sequences were located in different
domains of the capsid for NV and FH. The amino acid se-
quence FDLSLGPHLNPFLLH located in the shell domain
was found to be stimulatory to NV-immune splenocytes, and
the sequence CLLPQEWVQHFYQEAAPAQSDVALL lo-
cated in the P1 domain was found to be stimulatory to FH-
immune splenocytes. The identified sequences are unlikely to
contain residues important for receptor binding (19).
Alignments of capsid sequences of additional GI.1 and GII.4
strains to the stimulatory sequences within NV and FH, re-
spectively, revealed high homology to additional strains (100%
and 91.7%, respectively) (Fig. 5). Peptide stimulation of
splenocytes following immunization with heterologous strains
within these genoclusters resulted in variable levels of cross-
reactive IFN- responses (Fig. 6A and B). For example, mice
immunized with GII.4 strains LV97 and Hunter, which repre-
sent evolutionarily distinct strains that emerged immediately
before and after the FH strain, respectively (19), mounted
FIG. 5. Alignments of stimulatory NV and FH capsid peptide sequences. Identified stimulatory sequences within the NV (A) and FH
(B) capsids were aligned with corresponding sequences from other GI and GII strains. Yellow, amino acids completely conserved across human
genogroups; blue, amino acids completely conserved within genogroup; red, amino acids completely conserved within genocluster; green, variable.
VOL. 84, 2010 NOROVIRUS T CELL EPITOPES 8535
higher cross-reactive responses to FH peptides than mice im-
munized with their more evolutionarily distant GII.4 counter-
parts LV87 and Sakai. Together, these results suggest that T
cell epitopes are conserved within the GII.4 genocluster and
are likely to activate a memory T cell response upon subse-
quent challenge with genetically related strains. However, we
note that some epitopes may be evolving over time in geno-
clusters under high evolutionary pressure, such as the GII.4
cluster in human populations. These data suggest that future
human challenge studies and/or outbreak investigations should
consider evaluating homotypic and heterotypic memory T cell
responses against time-ordered and more distant genocluster
strains. In contrast, additional GI sequences outside the GI.1
genocluster were also highly conserved (86.7%) compared to
the stimulatory NV sequence, but splenocytes from other GI
VRP-vaccinated animals did not mount cross-reactive re-
sponses to the NV peptide. These BALB/c data are in contrast
to recent human data demonstrating GI VLP cross-reactive T
cell responses in NV-infected humans and likely represent
restrictions specific for the BALB/c major histocompatibility
complex (MHC), which recognized only a single NV stimula-
tory peptide. Alternatively, conserved epitopes may exist in
one or more other GI genoclusters not evaluated in our anal-
yses. In comparison, human T cell responses represent an
accumulated memory after multiple lifetime exposures, and
cells were stimulated with intact VLPs as opposed to peptides,
allowing for stimulation of the maximum variety of cells. Het-
erologous GII sequences outside the GII.4 genocluster were
less highly conserved (60%) to the stimulatory FH sequence;
however, splenocyte cultures following heterologous GII im-
munization induced cross-reactive responses to the FH pep-
tides. These findings suggest that specific residues within stim-
ulatory sequences are likely to elicit robust responses and may
not be dependent on the context of the entire sequence. Fur-
thermore, epitopes and cross-reactivity outcomes are likely to
be variable and strain dependent within and across geno-
groups. Sequences were not conserved across genogroups,
which is supported by our findings that stimulatory NV and FH
peptides did not stimulate splenocytes immune to strains out-
side the respective genogroups, and similar findings have been
noted for humans (17, 18).
Defining specific epitopes for T cell activation on distinct
norovirus capsids will reveal unknown antigenic and immuno-
genic relationships among norovirus strains. Using overlapping
peptide libraries, we were able to experimentally identify spe-
cific stimulatory peptides containing putative T cell epitopes.
Synthesis of truncated peptides for use in stimulatory assays
allowed for identification of required residues for epitope
identification. Epitopes for T cell activation in mice may be
different from those in humans; however, the mechanism(s) of
protection following infection is likely similar. The newly de-
veloped mouse norovirus challenge model will allow continued
investigation into the effect of the T cell response following
homologous or heterologous norovirus exposure as well as a
system in which to evaluate the efficacy of preventative thera-
pies triggering T cell-specific responses. These preliminary
FIG. 6. Stimulatory sequence cross-reactivity among norovirus strains. Following immunization with a panel of VRPs, splenocytes were
stimulated with NV GI.1-1968 peptide 9 (A) or FH GII.4-2002 peptide 46 or 47 (B and C) or unstimulated and were measured for IFN- secretion
by EIA. Stimulation with NV peptide 9 elicited significantly higher IFN- responses in WC (GI.1) immune splenocytes than other groups (P 
0.01) (A). Stimulation with FH 46 elicited significantly higher IFN- responses in all GII.4 immune groups (B) than in all non-GII.4 immune groups
(C) (Sak, P  0.05; other GII.4 groups, P  0.001), and M7 and HV (GII) immune splenocytes elicited higher responses than GI immune
splenocytes (P  0.01 and 0.05, respectively) (C). Stimulation with FH peptide 47 elicited significantly higher IFN- responses in LV97 and Hunt
(GII.4) groups than non-GII groups (P  0.01).
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studies will provide previously unattainable answers to ques-
tions that can bridge important issues in human medicine.
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